{"gene":"BRI3","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2009,"finding":"BRI3 interacts with APP and acts as an endogenous negative regulator of Aβ production; BRI3 overexpression reduces both alpha- and beta-APP cleavage, suggesting it inhibits secretase access to APP. BRI3 colocalizes with APP along neurites in differentiated N2a cells, and endogenous BRI3-APP complexes are detectable in mouse brain extract. Unlike BRI2, BRI3 shows negligible binding to the beta-secretase cleaved APP C-terminal fragment and is a poor gamma-cleavage inhibitor. RNAi knockdown of BRI3 increases Aβ secretion.","method":"Co-immunoprecipitation, colocalization (immunofluorescence), RNA interference with Aβ ELISA readout, APP fragment analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP in brain tissue, RNAi loss-of-function with biochemical readout, colocalization; multiple orthogonal methods in single focused study","pmids":["19366692"],"is_preprint":false},{"year":2005,"finding":"BACE1 (beta-secretase) interacts with BRI3 via the cytosolic tail of BACE1, as identified by yeast two-hybrid screening and confirmed by co-immunoprecipitation and colocalization. BRI3 is processed by the pro-protein convertase furin (and to a lesser extent PC7 and PC5A) into a C-terminal secreted ~4-kDa product.","method":"Yeast two-hybrid, co-immunoprecipitation, colocalization, pulse-chase analysis with furin/PC7/PC5A processing assays","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid identification plus reciprocal Co-IP and biochemical processing assays; single lab with multiple orthogonal methods","pmids":["15606899"],"is_preprint":false},{"year":2020,"finding":"NRBP1, acting as the substrate receptor of a Cullin-RING ubiquitin ligase (CRL) complex containing Cul2 and Cul4A, targets BRI3 (and BRI2) for proteasomal degradation. NRBP1 knockdown in neuronal cells increases BRI3 abundance and reduces Aβ production. Formation of the NRBP1 heterodimeric CRL is enhanced by TSC22D3 and TSC22D4 chaperone-like function.","method":"Biochemical characterization of CRL complex assembly, NRBP1 knockdown with Western blot and Aβ quantification, co-immunoprecipitation/mass spectrometry","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS identification of complex, knockdown with functional readout, mechanistic characterization of CRL assembly; multiple orthogonal methods in single study","pmids":["32160551"],"is_preprint":false},{"year":2015,"finding":"BRI3 binds protein phosphatase 1 (PP1) via a PP1-binding motif identified in silico and validated in vitro and in vivo; BRI3 is itself a substrate of PP1 (i.e., BRI3 is a phosphoprotein dephosphorylated by PP1). BRI3 colocalizes with PP1 in the perinuclear area, Golgi apparatus, and in neuronal processes and cell body.","method":"In silico motif identification, in vitro binding assay, co-immunoprecipitation (in vivo), site-directed mutagenesis of PP1 binding motif, colocalization (confocal microscopy)","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP validated in vitro and in vivo with mutagenesis; single lab","pmids":["26515131"],"is_preprint":false},{"year":2008,"finding":"BRI3 associates with SCG10 (a microtubule-destabilizing protein); this interaction blocks SCG10's ability to induce microtubule disassembly in vitro and stabilizes the microtubule network in intact PC12 cells. Co-expression of BRI3 with SCG10 attenuates SCG10-mediated neurite outgrowth induced by NGF.","method":"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, colocalization, in vitro microtubule polymerization/depolymerization turbidimetric assay, PC12 cell neurite outgrowth assay","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by GST pull-down and Co-IP, plus in vitro functional assay; single lab with multiple orthogonal methods","pmids":["18452648"],"is_preprint":false},{"year":2003,"finding":"BRI3 is involved in TNF-alpha-induced cell death; antisense-mediated suppression of BRI3 expression promotes resistance to TNF-induced cell death by >1000-fold in L929 cells but has no effect on other apoptotic inducers, indicating pathway-specific involvement. BRI3 was found to localize to lysosomes.","method":"Antisense RNA knockdown with TNF cell death assay (viability/apoptosis), lysosome localization by subcellular fractionation/imaging","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — loss-of-function with specific phenotypic readout and localization data; single lab, methods partially described in abstract","pmids":["14592447"],"is_preprint":false},{"year":2018,"finding":"The Bri3 BRICHOS domain interacts with Aβ40 and Aβ42 present in neurons and reduces Aβ42 amyloid fibril formation in vitro, but less efficiently than Bri2 BRICHOS. Bri3 immunoreactivity is decreased in AD brain homogenates compared to controls, and Bri3 deposits are found dispersed on AD plaques in mouse and human brain tissue.","method":"In vitro Aβ42 fibril formation assay, immunohistochemistry/immunofluorescence on mouse and human brain tissue, Western blot of brain homogenates","journal":"Journal of Alzheimer's disease reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution of BRICHOS–Aβ interaction with fibril assay plus tissue localization; single study with multiple methods","pmids":["30480246"],"is_preprint":false},{"year":2020,"finding":"Recombinant Bri3 BRICHOS domain forms larger oligomers than Bri2 BRICHOS, more efficiently prevents non-fibrillar protein aggregation, and less efficiently reduces Aβ42 fibril formation, indicating overlapping but quantitatively distinct chaperone activities between Bri2 and Bri3 BRICHOS.","method":"Recombinant protein production, size-exclusion chromatography/biophysical characterization, in vitro amyloid fibril formation assay, non-fibrillar aggregation assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified recombinant domain, multiple functional assays; single lab","pmids":["32555390"],"is_preprint":false},{"year":2018,"finding":"BRI3 interacts with IFITM3 and MGAT1 as identified by yeast two-hybrid screening of a human liver cDNA library, confirmed by co-transformation in yeast and co-immunoprecipitation from mammalian cell lines.","method":"Yeast two-hybrid, co-transformation, co-immunoprecipitation from mammalian cells","journal":"Turkish journal of biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP confirmation with no functional follow-up; single lab, single study","pmids":["30983867"],"is_preprint":false},{"year":2010,"finding":"BRI3 is a transcriptional target of the Wnt/β-catenin/TCF4 signaling pathway; its promoter contains TCF-binding elements, and BRI3 expression is upregulated upon active β-catenin/TCF signaling in hepatocellular carcinoma-derived Huh7 cells.","method":"SAGE, genome-wide microarray, in silico promoter analysis, qRT-PCR, ChIP, luciferase reporter assay, lithium treatment","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase reporter assay confirm direct transcriptional regulation; single lab with multiple orthogonal methods","pmids":["20538055"],"is_preprint":false}],"current_model":"BRI3 is a type II transmembrane brain-enriched protein that functions as an endogenous inhibitor of APP processing and Aβ production by interacting directly with APP and blocking secretase access; its stability is regulated by the NRBP1-CRL2/CRL4A ubiquitin ligase complex that targets it for degradation; it is processed by furin and interacts with BACE1 via its cytosolic tail; it binds and is dephosphorylated by PP1; its BRICHOS domain acts as a molecular chaperone that inhibits Aβ42 fibril formation; it associates with SCG10 to stabilize microtubules and attenuate NGF-induced neurite outgrowth; it participates in TNF-alpha-induced cell death via a lysosomal pathway; and its expression is transcriptionally regulated by Wnt/β-catenin/TCF4 signaling."},"narrative":{"mechanistic_narrative":"BRI3 is a brain-enriched transmembrane protein that acts as an endogenous negative regulator of amyloid precursor protein (APP) processing and amyloid-β (Aβ) production [PMID:19366692]. It binds APP directly and colocalizes with it along neurites, and its overexpression reduces both α- and β-cleavage of APP while knockdown increases Aβ secretion, consistent with BRI3 limiting secretase access to APP; unlike BRI2, it binds the β-cleaved APP C-terminal fragment poorly and is a weak γ-cleavage inhibitor [PMID:19366692]. BRI3 additionally engages the β-secretase machinery through a physical interaction with the cytosolic tail of BACE1, and is itself proteolytically matured by the convertase furin into a secreted C-terminal fragment [PMID:15606899]. A second, complementary anti-amyloidogenic activity resides in its BRICHOS domain, which binds Aβ40/Aβ42 and inhibits Aβ42 fibril formation in vitro, functioning as a molecular chaperone that more efficiently suppresses non-fibrillar aggregation but less efficiently blocks fibril formation than the related BRI2 BRICHOS domain [PMID:30480246, PMID:32555390]. BRI3 abundance is controlled post-translationally by an NRBP1-based Cullin-RING ligase (Cul2/Cul4A) that targets it for proteasomal degradation, such that NRBP1 depletion stabilizes BRI3 and lowers Aβ [PMID:32160551], and its expression is driven transcriptionally by Wnt/β-catenin/TCF4 signaling [PMID:20538055]. Beyond amyloid biology, BRI3 binds and is dephosphorylated by protein phosphatase 1 [PMID:26515131], stabilizes the microtubule network and attenuates NGF-induced neurite outgrowth through association with the microtubule-destabilizing protein SCG10 [PMID:18452648], and is required for TNF-α-induced lysosomal cell death [PMID:14592447].","teleology":[{"year":2003,"claim":"Established the first cellular function for BRI3, linking it specifically to death receptor signaling rather than general apoptosis.","evidence":"Antisense knockdown of BRI3 in L929 cells with TNF cell-death assay and lysosomal localization by fractionation/imaging","pmids":["14592447"],"confidence":"Medium","gaps":["No molecular effector linking BRI3 to the lysosomal death pathway identified","Pathway specificity tested in a single cell line"]},{"year":2005,"claim":"Connected BRI3 to the amyloidogenic machinery by identifying BACE1 as a partner and defining how BRI3 itself is processed.","evidence":"Yeast two-hybrid against BACE1 cytosolic tail, reciprocal Co-IP, colocalization, and furin/PC7/PC5A processing assays","pmids":["15606899"],"confidence":"High","gaps":["Functional consequence of BRI3-BACE1 binding on β-secretase activity not resolved","Role of the secreted ~4-kDa fragment unknown"]},{"year":2008,"claim":"Revealed a cytoskeletal role by showing BRI3 sequesters SCG10 to stabilize microtubules and restrain neurite outgrowth.","evidence":"Yeast two-hybrid, GST pull-down, Co-IP, in vitro microtubule turbidimetry, and PC12 neurite outgrowth assay","pmids":["18452648"],"confidence":"Medium","gaps":["In vivo relevance to neuronal development not established","Single lab without independent confirmation"]},{"year":2009,"claim":"Defined BRI3's central role as a direct APP binder and endogenous brake on Aβ production, distinguishing it mechanistically from BRI2.","evidence":"Reciprocal Co-IP from mouse brain, colocalization in N2a neurites, RNAi with Aβ ELISA and APP fragment analysis","pmids":["19366692"],"confidence":"High","gaps":["Structural basis for blocking secretase access not determined","Whether inhibition is steric or allosteric unresolved"]},{"year":2010,"claim":"Placed BRI3 expression under Wnt/β-catenin/TCF4 control, providing a transcriptional input to its abundance.","evidence":"SAGE/microarray, promoter TCF-element analysis, ChIP, luciferase reporter, and lithium treatment in Huh7 cells","pmids":["20538055"],"confidence":"Medium","gaps":["Demonstrated in hepatocellular carcinoma cells, not neurons","Link between Wnt-driven BRI3 levels and Aβ regulation not tested"]},{"year":2015,"claim":"Identified PP1 as a phosphatase that binds and dephosphorylates BRI3, implying its activity is phosphoregulated.","evidence":"In silico motif prediction, in vitro binding, in vivo Co-IP, PP1-motif mutagenesis, confocal colocalization","pmids":["26515131"],"confidence":"Medium","gaps":["Functional consequence of BRI3 phosphorylation state unknown","Kinase acting on BRI3 not identified"]},{"year":2020,"claim":"Demonstrated dual mechanisms governing BRI3's anti-amyloid action: post-translational degradation control and an intrinsic chaperone domain.","evidence":"Co-IP/MS of the NRBP1-Cul2/Cul4A CRL with knockdown and Aβ quantification; recombinant BRICHOS biophysics with in vitro fibril and aggregation assays","pmids":["32160551","32555390"],"confidence":"High","gaps":["Whether NRBP1-mediated degradation of BRI3 occurs in vivo brain not shown","Physiological relevance of distinct BRI3 vs BRI2 BRICHOS chaperone activities unclear"]},{"year":null,"claim":"How BRI3's diverse activities — APP/BACE1 binding, BRICHOS chaperone function, SCG10/microtubule regulation, PP1 dephosphorylation, and TNF-induced lysosomal death — are integrated within a single protein and coordinated in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of BRI3 or its complexes","Physiological role in vivo and in neurodegeneration not established by loss-of-function organismal studies","IFITM3/MGAT1 interactions lack functional follow-up"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[6,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[5]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1]}],"pathway":[],"complexes":[],"partners":["APP","BACE1","NRBP1","PP1","SCG10","IFITM3","MGAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95415","full_name":"Membrane protein BRI3","aliases":["Brain protein I3","pRGR2"],"length_aa":125,"mass_kda":13.6,"function":"Participates in tumor necrosis factor-alpha (TNF)-induced cell death (PubMed:14592447). May be a target of Wnt/beta-catenin signaling in the liver (PubMed:20538055)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/O95415/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRI3","classification":"Not Classified","n_dependent_lines":215,"n_total_lines":1208,"dependency_fraction":0.17798013245033112},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BRI3","total_profiled":1310},"omim":[{"mim_id":"615628","title":"BRAIN PROTEIN I3; BRI3","url":"https://www.omim.org/entry/615628"},{"mim_id":"615627","title":"BRI3-BINDING PROTEIN; BRI3BP","url":"https://www.omim.org/entry/615627"},{"mim_id":"609554","title":"INTEGRAL MEMBRANE PROTEIN 2C; ITM2C","url":"https://www.omim.org/entry/609554"},{"mim_id":"300222","title":"INTEGRAL MEMBRANE PROTEIN 2A; ITM2A","url":"https://www.omim.org/entry/300222"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRI3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O95415","domains":[{"cath_id":"-","chopping":"90-123","consensus_level":"high","plddt":84.7765,"start":90,"end":123}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95415","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95415-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95415-F1-predicted_aligned_error_v6.png","plddt_mean":65.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRI3","jax_strain_url":"https://www.jax.org/strain/search?query=BRI3"},"sequence":{"accession":"O95415","fasta_url":"https://rest.uniprot.org/uniprotkb/O95415.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95415/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95415"}},"corpus_meta":[{"pmid":"19366692","id":"PMC_19366692","title":"BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19366692","citation_count":48,"is_preprint":false},{"pmid":"11290423","id":"PMC_11290423","title":"Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11290423","citation_count":48,"is_preprint":false},{"pmid":"15606899","id":"PMC_15606899","title":"Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin.","date":"2005","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15606899","citation_count":37,"is_preprint":false},{"pmid":"32160551","id":"PMC_32160551","title":"NRBP1-Containing CRL2/CRL4A Regulates Amyloid β Production by Targeting BRI2 and BRI3 for Degradation.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32160551","citation_count":36,"is_preprint":false},{"pmid":"30480246","id":"PMC_30480246","title":"The Bri2 and Bri3 BRICHOS Domains Interact Differently with Aβ42 and Alzheimer Amyloid Plaques.","date":"2018","source":"Journal of Alzheimer's disease reports","url":"https://pubmed.ncbi.nlm.nih.gov/30480246","citation_count":31,"is_preprint":false},{"pmid":"14592447","id":"PMC_14592447","title":"bri3, a novel gene, participates in tumor necrosis factor-alpha-induced cell death.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14592447","citation_count":27,"is_preprint":false},{"pmid":"26617783","id":"PMC_26617783","title":"MicroRNA-323 regulates ischemia/reperfusion injury-induced neuronal cell death by targeting BRI3.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617783","citation_count":22,"is_preprint":false},{"pmid":"32555390","id":"PMC_32555390","title":"Recombinant Bri3 BRICHOS domain is a molecular chaperone with effect against amyloid formation and non-fibrillar protein aggregation.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32555390","citation_count":19,"is_preprint":false},{"pmid":"20538055","id":"PMC_20538055","title":"Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets.","date":"2010","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/20538055","citation_count":19,"is_preprint":false},{"pmid":"26515131","id":"PMC_26515131","title":"BRI2 and BRI3 are functionally distinct phosphoproteins.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26515131","citation_count":11,"is_preprint":false},{"pmid":"18452648","id":"PMC_18452648","title":"BRI3 associates with SCG10 and attenuates NGF-induced neurite outgrowth in PC12 cells.","date":"2008","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/18452648","citation_count":8,"is_preprint":false},{"pmid":"39766855","id":"PMC_39766855","title":"Comparative Genomic Analysis of Bacillus velezensis BRI3 Reveals Genes Potentially Associated with Efficient Antagonism of Sclerotinia sclerotiorum (Lib.) de Bary.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/39766855","citation_count":5,"is_preprint":false},{"pmid":"40855015","id":"PMC_40855015","title":"BRI3 Orchestrates Lipid Metabolism and Autophagy in Glioblastoma: Implications for Tumor Cell Resilience.","date":"2025","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40855015","citation_count":1,"is_preprint":false},{"pmid":"30983867","id":"PMC_30983867","title":"Identification of IFITM3 and MGAT1 as novel interaction partners of BRI3 by yeast two-hybrid screening.","date":"2018","source":"Turkish journal of biology = Turk biyoloji dergisi","url":"https://pubmed.ncbi.nlm.nih.gov/30983867","citation_count":1,"is_preprint":false},{"pmid":"16508092","id":"PMC_16508092","title":"Crystallization and preliminary X-ray analysis of the GST-fused human Bri3 N-terminal domain.","date":"2004","source":"Acta crystallographica. Section F, Structural biology and crystallization communications","url":"https://pubmed.ncbi.nlm.nih.gov/16508092","citation_count":1,"is_preprint":false},{"pmid":"42214380","id":"PMC_42214380","title":"A bacterial ally for nitrogen-fixing biofilm: enhancing the rhizosphere colonization of Stutzerimonas stutzeri A1501 with surfactin-producing Bacillus velezensis BRI3.","date":"2026","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/42214380","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9299,"output_tokens":2775,"usd":0.034761,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10026,"output_tokens":2904,"usd":0.061365,"stage2_stop_reason":"end_turn"},"total_usd":0.096126,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"BRI3 interacts with APP and acts as an endogenous negative regulator of Aβ production; BRI3 overexpression reduces both alpha- and beta-APP cleavage, suggesting it inhibits secretase access to APP. BRI3 colocalizes with APP along neurites in differentiated N2a cells, and endogenous BRI3-APP complexes are detectable in mouse brain extract. Unlike BRI2, BRI3 shows negligible binding to the beta-secretase cleaved APP C-terminal fragment and is a poor gamma-cleavage inhibitor. RNAi knockdown of BRI3 increases Aβ secretion.\",\n      \"method\": \"Co-immunoprecipitation, colocalization (immunofluorescence), RNA interference with Aβ ELISA readout, APP fragment analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP in brain tissue, RNAi loss-of-function with biochemical readout, colocalization; multiple orthogonal methods in single focused study\",\n      \"pmids\": [\"19366692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BACE1 (beta-secretase) interacts with BRI3 via the cytosolic tail of BACE1, as identified by yeast two-hybrid screening and confirmed by co-immunoprecipitation and colocalization. BRI3 is processed by the pro-protein convertase furin (and to a lesser extent PC7 and PC5A) into a C-terminal secreted ~4-kDa product.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, colocalization, pulse-chase analysis with furin/PC7/PC5A processing assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid identification plus reciprocal Co-IP and biochemical processing assays; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15606899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NRBP1, acting as the substrate receptor of a Cullin-RING ubiquitin ligase (CRL) complex containing Cul2 and Cul4A, targets BRI3 (and BRI2) for proteasomal degradation. NRBP1 knockdown in neuronal cells increases BRI3 abundance and reduces Aβ production. Formation of the NRBP1 heterodimeric CRL is enhanced by TSC22D3 and TSC22D4 chaperone-like function.\",\n      \"method\": \"Biochemical characterization of CRL complex assembly, NRBP1 knockdown with Western blot and Aβ quantification, co-immunoprecipitation/mass spectrometry\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS identification of complex, knockdown with functional readout, mechanistic characterization of CRL assembly; multiple orthogonal methods in single study\",\n      \"pmids\": [\"32160551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BRI3 binds protein phosphatase 1 (PP1) via a PP1-binding motif identified in silico and validated in vitro and in vivo; BRI3 is itself a substrate of PP1 (i.e., BRI3 is a phosphoprotein dephosphorylated by PP1). BRI3 colocalizes with PP1 in the perinuclear area, Golgi apparatus, and in neuronal processes and cell body.\",\n      \"method\": \"In silico motif identification, in vitro binding assay, co-immunoprecipitation (in vivo), site-directed mutagenesis of PP1 binding motif, colocalization (confocal microscopy)\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP validated in vitro and in vivo with mutagenesis; single lab\",\n      \"pmids\": [\"26515131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRI3 associates with SCG10 (a microtubule-destabilizing protein); this interaction blocks SCG10's ability to induce microtubule disassembly in vitro and stabilizes the microtubule network in intact PC12 cells. Co-expression of BRI3 with SCG10 attenuates SCG10-mediated neurite outgrowth induced by NGF.\",\n      \"method\": \"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, colocalization, in vitro microtubule polymerization/depolymerization turbidimetric assay, PC12 cell neurite outgrowth assay\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by GST pull-down and Co-IP, plus in vitro functional assay; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18452648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BRI3 is involved in TNF-alpha-induced cell death; antisense-mediated suppression of BRI3 expression promotes resistance to TNF-induced cell death by >1000-fold in L929 cells but has no effect on other apoptotic inducers, indicating pathway-specific involvement. BRI3 was found to localize to lysosomes.\",\n      \"method\": \"Antisense RNA knockdown with TNF cell death assay (viability/apoptosis), lysosome localization by subcellular fractionation/imaging\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — loss-of-function with specific phenotypic readout and localization data; single lab, methods partially described in abstract\",\n      \"pmids\": [\"14592447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The Bri3 BRICHOS domain interacts with Aβ40 and Aβ42 present in neurons and reduces Aβ42 amyloid fibril formation in vitro, but less efficiently than Bri2 BRICHOS. Bri3 immunoreactivity is decreased in AD brain homogenates compared to controls, and Bri3 deposits are found dispersed on AD plaques in mouse and human brain tissue.\",\n      \"method\": \"In vitro Aβ42 fibril formation assay, immunohistochemistry/immunofluorescence on mouse and human brain tissue, Western blot of brain homogenates\",\n      \"journal\": \"Journal of Alzheimer's disease reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution of BRICHOS–Aβ interaction with fibril assay plus tissue localization; single study with multiple methods\",\n      \"pmids\": [\"30480246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Recombinant Bri3 BRICHOS domain forms larger oligomers than Bri2 BRICHOS, more efficiently prevents non-fibrillar protein aggregation, and less efficiently reduces Aβ42 fibril formation, indicating overlapping but quantitatively distinct chaperone activities between Bri2 and Bri3 BRICHOS.\",\n      \"method\": \"Recombinant protein production, size-exclusion chromatography/biophysical characterization, in vitro amyloid fibril formation assay, non-fibrillar aggregation assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified recombinant domain, multiple functional assays; single lab\",\n      \"pmids\": [\"32555390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRI3 interacts with IFITM3 and MGAT1 as identified by yeast two-hybrid screening of a human liver cDNA library, confirmed by co-transformation in yeast and co-immunoprecipitation from mammalian cell lines.\",\n      \"method\": \"Yeast two-hybrid, co-transformation, co-immunoprecipitation from mammalian cells\",\n      \"journal\": \"Turkish journal of biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP confirmation with no functional follow-up; single lab, single study\",\n      \"pmids\": [\"30983867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRI3 is a transcriptional target of the Wnt/β-catenin/TCF4 signaling pathway; its promoter contains TCF-binding elements, and BRI3 expression is upregulated upon active β-catenin/TCF signaling in hepatocellular carcinoma-derived Huh7 cells.\",\n      \"method\": \"SAGE, genome-wide microarray, in silico promoter analysis, qRT-PCR, ChIP, luciferase reporter assay, lithium treatment\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase reporter assay confirm direct transcriptional regulation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"20538055\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRI3 is a type II transmembrane brain-enriched protein that functions as an endogenous inhibitor of APP processing and Aβ production by interacting directly with APP and blocking secretase access; its stability is regulated by the NRBP1-CRL2/CRL4A ubiquitin ligase complex that targets it for degradation; it is processed by furin and interacts with BACE1 via its cytosolic tail; it binds and is dephosphorylated by PP1; its BRICHOS domain acts as a molecular chaperone that inhibits Aβ42 fibril formation; it associates with SCG10 to stabilize microtubules and attenuate NGF-induced neurite outgrowth; it participates in TNF-alpha-induced cell death via a lysosomal pathway; and its expression is transcriptionally regulated by Wnt/β-catenin/TCF4 signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRI3 is a brain-enriched transmembrane protein that acts as an endogenous negative regulator of amyloid precursor protein (APP) processing and amyloid-β (Aβ) production [#0]. It binds APP directly and colocalizes with it along neurites, and its overexpression reduces both α- and β-cleavage of APP while knockdown increases Aβ secretion, consistent with BRI3 limiting secretase access to APP; unlike BRI2, it binds the β-cleaved APP C-terminal fragment poorly and is a weak γ-cleavage inhibitor [#0]. BRI3 additionally engages the β-secretase machinery through a physical interaction with the cytosolic tail of BACE1, and is itself proteolytically matured by the convertase furin into a secreted C-terminal fragment [#1]. A second, complementary anti-amyloidogenic activity resides in its BRICHOS domain, which binds Aβ40/Aβ42 and inhibits Aβ42 fibril formation in vitro, functioning as a molecular chaperone that more efficiently suppresses non-fibrillar aggregation but less efficiently blocks fibril formation than the related BRI2 BRICHOS domain [#6, #7]. BRI3 abundance is controlled post-translationally by an NRBP1-based Cullin-RING ligase (Cul2/Cul4A) that targets it for proteasomal degradation, such that NRBP1 depletion stabilizes BRI3 and lowers Aβ [#2], and its expression is driven transcriptionally by Wnt/β-catenin/TCF4 signaling [#9]. Beyond amyloid biology, BRI3 binds and is dephosphorylated by protein phosphatase 1 [#3], stabilizes the microtubule network and attenuates NGF-induced neurite outgrowth through association with the microtubule-destabilizing protein SCG10 [#4], and is required for TNF-α-induced lysosomal cell death [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the first cellular function for BRI3, linking it specifically to death receptor signaling rather than general apoptosis.\",\n      \"evidence\": \"Antisense knockdown of BRI3 in L929 cells with TNF cell-death assay and lysosomal localization by fractionation/imaging\",\n      \"pmids\": [\"14592447\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No molecular effector linking BRI3 to the lysosomal death pathway identified\", \"Pathway specificity tested in a single cell line\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connected BRI3 to the amyloidogenic machinery by identifying BACE1 as a partner and defining how BRI3 itself is processed.\",\n      \"evidence\": \"Yeast two-hybrid against BACE1 cytosolic tail, reciprocal Co-IP, colocalization, and furin/PC7/PC5A processing assays\",\n      \"pmids\": [\"15606899\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Functional consequence of BRI3-BACE1 binding on β-secretase activity not resolved\", \"Role of the secreted ~4-kDa fragment unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a cytoskeletal role by showing BRI3 sequesters SCG10 to stabilize microtubules and restrain neurite outgrowth.\",\n      \"evidence\": \"Yeast two-hybrid, GST pull-down, Co-IP, in vitro microtubule turbidimetry, and PC12 neurite outgrowth assay\",\n      \"pmids\": [\"18452648\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"In vivo relevance to neuronal development not established\", \"Single lab without independent confirmation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined BRI3's central role as a direct APP binder and endogenous brake on Aβ production, distinguishing it mechanistically from BRI2.\",\n      \"evidence\": \"Reciprocal Co-IP from mouse brain, colocalization in N2a neurites, RNAi with Aβ ELISA and APP fragment analysis\",\n      \"pmids\": [\"19366692\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Structural basis for blocking secretase access not determined\", \"Whether inhibition is steric or allosteric unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed BRI3 expression under Wnt/β-catenin/TCF4 control, providing a transcriptional input to its abundance.\",\n      \"evidence\": \"SAGE/microarray, promoter TCF-element analysis, ChIP, luciferase reporter, and lithium treatment in Huh7 cells\",\n      \"pmids\": [\"20538055\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Demonstrated in hepatocellular carcinoma cells, not neurons\", \"Link between Wnt-driven BRI3 levels and Aβ regulation not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified PP1 as a phosphatase that binds and dephosphorylates BRI3, implying its activity is phosphoregulated.\",\n      \"evidence\": \"In silico motif prediction, in vitro binding, in vivo Co-IP, PP1-motif mutagenesis, confocal colocalization\",\n      \"pmids\": [\"26515131\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Functional consequence of BRI3 phosphorylation state unknown\", \"Kinase acting on BRI3 not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated dual mechanisms governing BRI3's anti-amyloid action: post-translational degradation control and an intrinsic chaperone domain.\",\n      \"evidence\": \"Co-IP/MS of the NRBP1-Cul2/Cul4A CRL with knockdown and Aβ quantification; recombinant BRICHOS biophysics with in vitro fibril and aggregation assays\",\n      \"pmids\": [\"32160551\", \"32555390\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Whether NRBP1-mediated degradation of BRI3 occurs in vivo brain not shown\", \"Physiological relevance of distinct BRI3 vs BRI2 BRICHOS chaperone activities unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRI3's diverse activities — APP/BACE1 binding, BRICHOS chaperone function, SCG10/microtubule regulation, PP1 dephosphorylation, and TNF-induced lysosomal death — are integrated within a single protein and coordinated in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No structural model of BRI3 or its complexes\", \"Physiological role in vivo and in neurodegeneration not established by loss-of-function organismal studies\", \"IFITM3/MGAT1 interactions lack functional follow-up\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APP\", \"BACE1\", \"NRBP1\", \"PP1\", \"SCG10\", \"IFITM3\", \"MGAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}